Table 3.

Various international neoadjuvant protocols for osteosarcoma with outcomes

Study details	N	Chemotherapy	Good histological response rate (>90% necrosis)	EFS	OS
MSKCC T10 [37]	153	Preop-Mtx Post op- GR-MTX, BCD PR-APBCD	34%	72% (5years)	82% (5years)
MSKCC T12 [38]	73	Preop-MTX+BCD Post op GR-MBCD PR-AP	44%	73% (5years)	78% (5years)
IOR OS-2 39	164	Preop-MAP Post op GR-MAP PR-MAP + IE	71%		75% (5years)
EOI study 2 [40]	391	Arm A-AP ARM B MA + BCP/AP, similar to T10, not response tailored	30%	44% (5years)	55% (5years)
EOI study 3 [41]	504	DP with g-CSF	51%	37% (5years)	58% (5years)
COSS 86 [42]	171	MAP, I in high risk	68%	66% (10years)	75% (10years)
INT0133 [43]	617	MAP ± I and mifamurtide	45%	64% (6years)	74% (6years)
EURAMOS 1 [44]	716	Preop-MAP Post OP GR-MAP PR-MAP/IE	72.6% with MAP	60% vs 57% at 3 years	OS 77% vs 72% at 3 years (no difference)

MTX/M methotrexate, A adriamycin, P cisplatin, I ifosfamide, E etoposide, B bleomycin, EFS event-free survival, OS overall survival, GR good response, PR poor response, g-CSF granulocyte colony-stimulating factor